Business Daily Media

Men's Weekly

.

Alterity Therapeutics: Appendix 4C - Q4 FY22 Quarterly Cash Flow Report

  • Written by PR Newswire
Alterity Therapeutics: Appendix 4C - Q4 FY22 Quarterly Cash Flow Report
  • Phase 2 clinical trial for ATH434 commences in New Zealand and patient enrolment begins
  • Regulatory approval from the U.K. and Italian regulatory agencies to proceed with the Phase 2 trial
  • A$4.1 million R&D Tax Incentive Scheme refund
  • Cash balance on 30 June 2022 of A$34.8M

MELBOURNE, Australia and SAN FRANCISCO, July 22, 2022 /PRNewswire/...

Baby boomers are driving development feasibility leading to larger apartments

As residential developers continue to grapple with feasibility issues on apartment projects, the sector is struggling to deliver volumes of new st...

Hays launches FY25/26 Salary Guide: ‘Salary Paradox’ deepens as pay rises fail Australians

Rising dissatisfaction with pay, progression and perks is fuelling a new wave of career change in FY25/26, as Australians demand more from employe...

Australian Businesses Still Stuck in the AI Hype Cycle

Data Governance Failures, ROI Gaps and Unclear Strategy Slowing Progress Despite artificial intelligence (AI) dominating headlines and boardroom ag...

How to ensure your manufacturing business survives international tariff turmoil

Optimising your operations in FY2026 will help you combat the challenges of a volatile trading environment. Up, down, in out…Since the commence...

Why Apptio is Enhancing Visibility into AI and Hybrid Cloud

AI investments have become a strategic priority for business with the mindset that if you're not using AI, you're falling behind. But according to...

Beyond borders: Building a scalable strategy for international hiring

For many Australian businesses, growth increasingly depends on thinking beyond local borders.  As wage pressures rise, and specialised talent pool...

Sell by LayBy